PTC Therapeutics' Phase 2 CardinALS trial of utreloxastat in amyotrophic lateral sclerosis (ALS) failed to meet its primary endpoint of slowing disease progression.
PTC Therapeutics has submitted three approval applications to the FDA, including sepiapterin for PKU, Translarna for nmDMD, and a BLA for AADC deficiency gene therapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.